These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 17872966

  • 1. Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology.
    Wray J, Bishop-Bailey D.
    Exp Physiol; 2008 Jan; 93(1):148-54. PubMed ID: 17872966
    [Abstract] [Full Text] [Related]

  • 2. Peroxisome proliferator-activated receptors and inflammation.
    Moraes LA, Piqueras L, Bishop-Bailey D.
    Pharmacol Ther; 2006 Jun; 110(3):371-85. PubMed ID: 16168490
    [Abstract] [Full Text] [Related]

  • 3. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD.
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [Abstract] [Full Text] [Related]

  • 4. Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful?
    Chen R, Liang F, Moriya J, Yamakawa J, Takahashi T, Shen L, Kanda T.
    Int J Cardiol; 2008 Nov 12; 130(2):131-9. PubMed ID: 18582964
    [Abstract] [Full Text] [Related]

  • 5. Role of cytochrome P450 2C epoxygenases in hypoxia-induced cell migration and angiogenesis in retinal endothelial cells.
    Michaelis UR, Xia N, Barbosa-Sicard E, Falck JR, Fleming I.
    Invest Ophthalmol Vis Sci; 2008 Mar 12; 49(3):1242-7. PubMed ID: 18326754
    [Abstract] [Full Text] [Related]

  • 6. [Nuclear Receptor PPARs and magnesium].
    Fujii H.
    Clin Calcium; 2005 Nov 12; 15(11):52-64. PubMed ID: 16272614
    [Abstract] [Full Text] [Related]

  • 7. Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, re-exploring secondary organ complications of spontaneously hypertensive rats.
    Sun L, Ke Y, Zhu CY, Tang N, Tian DK, Gao YH, Zheng JP, Bian K.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2305-11. PubMed ID: 19080338
    [Abstract] [Full Text] [Related]

  • 8. Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning.
    Gauthier KM, Yang W, Gross GJ, Campbell WB.
    J Cardiovasc Pharmacol; 2007 Dec 20; 50(6):601-8. PubMed ID: 18091575
    [Abstract] [Full Text] [Related]

  • 9. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
    Xu X, Zhang XA, Wang DW.
    Adv Drug Deliv Rev; 2011 Jul 18; 63(8):597-609. PubMed ID: 21477627
    [Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ, Usher MG, Mortensen RM.
    Circ Res; 2008 Feb 15; 102(3):283-94. PubMed ID: 18276926
    [Abstract] [Full Text] [Related]

  • 11. PPAR and Pain.
    Maeda T, Kishioka S.
    Int Rev Neurobiol; 2009 Feb 15; 85():165-77. PubMed ID: 19607969
    [Abstract] [Full Text] [Related]

  • 12. Epoxyeicosatrienoic acids, cell signaling and angiogenesis.
    Fleming I.
    Prostaglandins Other Lipid Mediat; 2007 Jan 15; 82(1-4):60-7. PubMed ID: 17164133
    [Abstract] [Full Text] [Related]

  • 13. PPARs and their effects on the cardiovascular system.
    Oyekan A.
    Clin Exp Hypertens; 2011 Jan 15; 33(5):287-93. PubMed ID: 21721973
    [Abstract] [Full Text] [Related]

  • 14. DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation.
    Fleming I.
    Trends Pharmacol Sci; 2007 Sep 15; 28(9):448-52. PubMed ID: 17764757
    [Abstract] [Full Text] [Related]

  • 15. Detection of EETs and HETE-generating cytochrome P-450 enzymes and the effects of their metabolites on myometrial and vascular function.
    Pearson T, Warren AY, Barrett DA, Khan RN.
    Am J Physiol Endocrinol Metab; 2009 Sep 15; 297(3):E647-56. PubMed ID: 19549792
    [Abstract] [Full Text] [Related]

  • 16. Pioglitazone inhibits homocysteine-induced migration of vascular smooth muscle cells through a peroxisome proliferator-activated receptor gamma-independent mechanism.
    Li L, Gao PJ, Xi R, Wu CF, Zhu DL, Yan J, Lu GP.
    Clin Exp Pharmacol Physiol; 2008 Dec 15; 35(12):1471-6. PubMed ID: 18759864
    [Abstract] [Full Text] [Related]

  • 17. Lipoxygenase-derived metabolites are regulators of peroxisome proliferator-activated receptor gamma-2 expression in human vascular smooth muscle cells.
    Limor R, Sharon O, Knoll E, Many A, Weisinger G, Stern N.
    Am J Hypertens; 2008 Feb 15; 21(2):219-23. PubMed ID: 18202670
    [Abstract] [Full Text] [Related]

  • 18. Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors.
    Lee TI, Kao YH, Chen YC, Chen YJ.
    Eur J Clin Invest; 2009 Jan 15; 39(1):23-30. PubMed ID: 19067734
    [Abstract] [Full Text] [Related]

  • 19. Emerging role of epoxyeicosatrienoic acids in coronary vascular function.
    Larsen BT, Gutterman DD, Hatoum OA.
    Eur J Clin Invest; 2006 May 15; 36(5):293-300. PubMed ID: 16634832
    [Abstract] [Full Text] [Related]

  • 20. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions.
    Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W.
    Prog Lipid Res; 2006 Mar 15; 45(2):120-59. PubMed ID: 16476485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.